title: Adenoviral delivery of low-density lipoprotein receptors to hyperlipidemic rabbits: receptor expression modulates high-density lipoproteins.
abstract: Plasma concentrations of low-density lipoproteins (LDLs) and high-density lipoproteins (HDLs) are inversely related in several dyslipoproteinemias. To elucidate the interactions between these lipoproteins, we used a recombinant adenovirus (hLDLR-rAdV) to express human LDL receptors (hLDLRs) in LDL receptor-deficient rabbits. hLDLR-rAdV administration resulted in hepatocyte expression and a reduction of total, intermediate-density lipoprotein (IDL), and LDL cholesterol. In addition, we found that hLDLR-rAdV treatment induced (1) increased very-low-density lipoprotein (VLDL) cholesterol, (2) increased VLDL, IDL and LDL triglycerides, (3) decreased alpha- and pre-beta-migrating apolipoprotein E (apo E) and decreased pre-beta-migrating apo A-I at 2 to 4 days posttreatment, and (4) increased total plasma apo A-I and pre-beta-migrating apo A-I beginning 8 to 10 days posttreatment. Virtually all plasma apo A-I was present on alpha- and pre-beta-HDL. Pre-beta-HDL particles with size and electrophoretic properties consistent with nascent HDL demonstrated the greatest relative apo A-I enrichment following hLDLR-rAdV treatment. In summary, enhanced expression of hepatocyte LDLRs by hLDLR-rAdV treatment markedly altered apo A-I-containing lipoproteins and IDL and LDL. The use of recombinant viruses to express physiologically relevant genes in intact animals, analogous to transfection of cells in culture, provides a new strategy for the evaluation of effects of specific gene products on metabolic systems in vivo.
authors.affiliation: Molecular Disease Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD 20892-1666, USA.
authors.forename: D R
authors.initials: DR
authors.lastname: Brown
authors.forename: M E
authors.initials: ME
authors.lastname: Brousseau
authors.forename: R D
authors.initials: RD
authors.lastname: Shamburek
authors.forename: G D
authors.initials: GD
authors.lastname: Talley
authors.forename: S
authors.initials: S
authors.lastname: Meyn
authors.forename: S J
authors.initials: SJ
authors.lastname: Demosky
authors.forename: S
authors.initials: S
authors.lastname: Santamarina-Fojo
authors.forename: H B
authors.initials: HB
authors.lastname: Brewer
authors.forename: J M
authors.initials: JM
authors.lastname: Hoeg
mesh_terms: D000256:Adenoviridae / Q000235:genetics*; D000818:Animals; D001161:Arteriosclerosis / Q000378:metabolism / Q000628:therapy; D002784:Cholesterol / Q000378:metabolism; D015316:Genetic Therapy; D005822:Genetic Vectors; D006720:Homozygote; D006801:Humans; D006949:Hyperlipidemias / Q000378:metabolism / Q000628:therapy; D008075:Lipoproteins, HDL / Q000235:genetics*; D008297:Male; D011817:Rabbits; D011973:Receptors, LDL / Q000235:genetics*
chemical_list: D008075:Lipoproteins, HDL; D011973:Receptors, LDL; D002784:Cholesterol